Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lowtrade.. Would you take a look at ISR
Up 10 cents on unusually high volume.
Small news item today.
Thanks in advance.
NEWS OUT! Presenting at ASTRO 9/22-24
IsoRay's Cesium-131 Cancer Treatment Products and Results Will Be Discussed in a Number of Papers Presented During the Americ...
Today : Tuesday 13 August 2013
IsoRay Inc. (NYSE MKT: ISR) (NYSE Amex: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth at the 55th Annual Meeting of the American Society for Radiation Oncology (ASTRO). The annual meeting will take place September 22-24, 2013 in Atlanta, Georgia at the Georgia World Congress Center, and a number of papers are scheduled to be presented at the annual meeting on results achieved using IsoRay's products.
According to IsoRay CEO Dwight Babcock, "IsoRay now has more sales representatives speaking to the benefits of brachytherapy and presenting our products at new venues. We are seeing increased inquiries from the medical community about IsoRay's Cesium-131 (Cs-131) seeds, seed sutured mesh and GliaSite® for the treatment of a wide array of cancers throughout the body including brain, lung, ocular, gynecologic and prostate cancers. Our products offer an important advance over previous brain, head and neck, lung, prostate, abdominal wall and gynecological cancer treatments. With a number of papers being presented at ASTRO, we are encouraged as all of them showed very positive results realized in treating metastasized brain cancers, lung cancer and prostate cancer using Cs-131 or GliaSite®. Medical thought leaders recognize the need for a new powerful weapon in the battle against cancer and we believe Cesium-131 is that solution."
IsoRay has participated over the last quarter in the following industry shows, expanding its product awareness to differing specialists while sharing the benefits of Cesium-131 in their efforts to fight cancer:
1. American Brachytherapy Society (ABS) in New Orleans
2. American Association for Thoracic Surgery (AATS) in Minneapolis, Minnesota
3. American Association of Physicists in Medicine (AAPM) in Indianapolis, Indiana
IsoRay is also pleased to announce that Brigham and Women's (an affiliate of Harvard) and University Medical Center of Princeton have both recently begun treating patients using IsoRay products. Brigham and Women's has treated brain cancer and University Medical Center of Princeton has begun treating prostate cancer.
IsoRay's Cesium-131 sutured seeds, stranded mesh and the GliaSite® radiation therapy system each give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of brain tumor removal. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy brain and lung tissue as well as critical structures compared to other alternative treatments. IsoRay's cancer fighting products reduce the ability of the tumor to recur, which means important benefits for patients in longevity as well as quality of life.
IsoRay is the exclusive manufacturer of Cesium-131. Cesium-131 is the first new isotope to be available in seed form for brachytherapy in approximately 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices. IsoRay also distributes the GliaSite® radiation therapy system, used to treat brain cancers.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray (http://www.facebook.com/#/IsoRay). Follow us on Twitter @Isoray (https://twitter.com/#!/Isoray).
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed and its various delivery formats, the advantages of the Gliasite® delivery system, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether the use of GliaSite® or Cesium-131 will increase or continue, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of early clinical studies, patient results achieved with Cesium-131 or the Gliasite® delivery system, successful completion of future research and development activities, our ability to receive and maintain all required regulatory approvals in the U.S. and internationally, continued compliance with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
Contact:
IsoRay Medical
(509) 375-1202
Info@Isoray.com
With these approvals does it mean that sales
will begin immediately or are they still going to wait for a partner to do the marketing,etc?
Or will they wait for more national approvals?
Alleyba1... While I am enthused by your
optimism, I want some of what you are smoking!
Or did Rapidmelts technology incorporate that into a melt away tab? And that is what you are ingesting?? LOL
Wouldn't that be interesting. Medical marijuana in a rapidmelt delivery!!
Does the Judge have the authority to extend
the life of the Patent?
Thus increasing the length of RR
hfb.. thanks for your reply
Thats amazing that Bob would not be aware of the PR content. He was the one that issued it! LOL...
I know one share is not gonna make or break my account, but I would rather have it than not. Anyway, it gives us something to talk about while we wait for the real money.
GLTA
mr-mem... Same thing happened to me
Even though the press release says it will be rounded up. I figure I will wait a few days for one share before I complain.
Per the PR:
As a result of the implementation of the reverse stock split, every thirteen shares of issued and outstanding common stock will be converted into one share of common stock. No fractional shares will be issued in connection with the reverse stock split and in lieu thereof, Marathon will round such share amount up to the next whole number.
Maybe if we all send them a message they will adjust up our accounts!
TD Ameritrade....
My shares are now properly credited in my account.
Anyone else?
Good News From TD Ameritrade...
Your shares of Marathon Patent are held in street name and are held at the DTCC (Depository Trust and Clearing Corporation) which is a central depository where most brokerages hold shares in electronic form. The DTCC works directly with transfer agents for a majority of the major brokerage firms. As the DTCC is another intermediary between us and the transfer agent, us contacting them would not expedite this reorganization.
However, the DTCC has informed us that they are anticipating receiving the new, post-split shares of Marathon Patent Group tomorrow, 7/31/2013. You should see your account updated by close of business tomorrow.
Sincerely,
David Nelson
Corporate Actions and Dividends
TD Ameritrade, Division of TD Ameritrade, Inc.
Today's Update on Split....
I contacted the Transfer agent and the following is her response. I guess we will have to have some patience.
"I deal with shareholders with shares in their name. However, my two cents on the comments you sent me: The broker is correct. If the shares are held by DTC, they have to wait until DTC allocates the new shares to each broker that is a participant. Then the participant broker adjust the shareholders accounts. Corporate actions like a reverse split take time. Sometimes up to a month. Hopefully DTC will have the adjustments done shortly. Good luck!"
EQUITY STOCK TRANSFER
Nora Marckwordt | Senior Operations Specialist
110 Greene St. Suite 403
New York, NY 10012
P 917.746.4595
F 347.584.3644
www.equitystock.com
Thanks for the update...
I just received the following email from Ameritrade:
Thank you for your reply. Unfortunately, this process is really dependant on how fast the issuer and legal counsel of the company are at supplying the necessary documentation to DTC. Then DTC still has to review it. If you would like, you may contact the transfer agent of the company, Equity Stock Transfer, to see if they may give you a status. I have included their contact info below:
Phone: 917.746.4597
Email: info@nullequitystock.com
DTC still has not provided us with a date of completion and there is not a way we can ask them to speed up their process. Unfortunately with bulletin board securities, these actions may take longer. Again, once we do receive the new shares, your account is updated the same day. If you have any additional questions, you may reply to this email or contact our Corporate Actions/Dividends team at 888-723-8504 option 1, Monday through Friday, from 9 a.m. to 5:30 p.m. ET (excluding market holidays).
Sincerely,
Matthew Green
Registered Representative
Corporate Actions & Dividends Specialist
Division of TD Ameritrade Inc.
Maybe next month NBRI finds a few of these!
This particular site was overlooked for 160 years, Ruby is untouched for a lot less time! Go NBRI!!!
Amateur Prospector Finds $300,000 Gold Nugget
January 18th, 2013
201Broken News Daily Reports, An amateur prospector was walking in the Australian bush, when he found a 5.5 kilogram gold nugget worth $300,000. It was buried 60 centimeters underground and is one of the rarest finds of its kind. The man made the discovery on a site near Ballarat, Australia that had been mined by prospectors for more than 160 years. 160 years!? I guess, Australians never really got the whole “rush” part of “Gold Rush”.
Read more at http://marketdailynews.com/2013/01/18/amateur-prospector-finds-300000-gold-nugget/#q0twITjvm8s9KhvY.99
3rd Possible story...
Maybe news on ZTE
Not to beat a dead horse, but here is another follow up...
Thank you for your inquiry. I can confirm that MARATHON PATENT GROUP INC (ticker MARA) has performed 1 for 13 reverse split effective 7/22/2013. When a security performs a reverse split, it requires us to remove the original position from our records and replace them with new shares we receive from the company. Accounts are then updated to the new side once the Depository Trust Company (DTC) receives the new shares. Regarding MARA (now under temporary ticker MARAD), unfortunately we do not have any indication as to when the company will be able to allocate the new shares to our depository. DTC is currently working with the issuer and legal counsel of the company to make the new side DTC eligible so we can still hold there in electronic form. However, once we do receive the new shares, your account is updated the same day. Other brokerage houses may front the new shares to their clients, however, TD Ameritrade does not practice this as the risk is way too great. Please contact us again if you have any additional questions.
Sincerely,
Corporate Actions & Dividends Specialist
Division of TD Ameritrade Inc.
Follow up from Ameritrade.
Just received an email from Ameritrade that their Corporate Actions Department has not received a date of completion yet from the company.
So, they are blaming the delay on Marathon!
Thanks...
I guess that is a good thing then.. It keeps us from selling too early!
Go MARA 7.25 (.5576 pre split)as we speak..
MARAD... TD Ameritrade Slow
Ameritrade still has not adjusted my account.. Anybody esle having the same problem?
TIA
Prince of Cambridge
Send a care package to Prince William and Duchess Kate for the new little Prince!
Celtics...
Took your advice and added 3,000
Thanks for all you do!
NBM
Go Yankees...oops I mean SCRC (ok, Yankees too!--LOL)
Smitter...Thank you for all your DD..
I just picked up some of those cheapies at .0699
More great news today.
Can't wait for production to start...
GLTA
News... Monday, July 8, 2013
Cesium-131 Implant Provides the Needed Radiation to Treat This Deadly Cancer
Richland, WA, July 8, 2013 – (eTeligis via Accesswire) -- IsoRay Inc. (ISR) (http://www.Isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced another milestone in the treatment of rectal cancer using its groundbreaking Cesium-131 (Cs-131) seed sutured mesh for internal radiation therapy.
Drs. J. Steven Johnson of Lewis Hall Singletary Oncology Center and Alan S. Waller of South GA Surgical Associates and the John D. Archbold Memorial Hospital, Thomasville, Georgia, successfully completed the world's first pelvic floor implant using IsoRay Medical's Cesium-131 brachytherapy mesh. Cesium-131 seeded mesh is a form of cancer fighting radiation therapy that is implanted at the time of surgical removal of tumors and immediately attacks the residual cancer cells.
Dr. Johnson commented, "When rectal cancers become locally advanced, they recur frequently after surgery. Radiation is therefore performed, but the amount of radiation required to successfully treat the disease is often limited with existing technologies and has the potential to injure the patient. With the Cesium-131 seeded mesh we can get the optimal dose to the area of concern at the time of surgery which we think is a real benefit for the patient."
Recent innovations in cancer surgery have allowed surgeons to remove less healthy tissue than in years past. In these cases, however, radiation therapy becomes a critical addition to the treatment of the cancer. IsoRay Medical supplies multiple radiation based products that can be used at the time of surgery to deliver this needed radiation, ensuring direct irradiation of the cancer-involved target while minimizing the damaging effects of radiation on healthy tissues.
Dr. Johnson added, "We have had great success with Cesium-131 in treating prostate and lung cancers and continue to look for other applications such as these rectal cancers. We can be very confident that a high radiation dose is deposited right where the tumor was, and where cells may still be present. We like the short half-life of Cesium-131 for cancer-controlling reasons and for the convenience that it delivers for the patient."
IsoRay Chairman and CEO Dwight Babcock congratulated the pioneering cancer physicians, "We are very pleased to be working with innovative cancer physicians such as Drs. Johnson and Waller. We believe that collaboration between the radiation oncologist and the surgical oncologist offers patients the best possible treatment."
IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
IsoRay CEO Dwight Babcock says this is just the latest application in cancer treatment representing the continued expansion of use of the Company's pioneering Cesium-131 brachytherapy seeds and liquid isotopes. "We are advancing our domestic and international goal of creating widespread awareness and adoption of Cesium-131. The exceptional results that have been realized in treating such a wide array of cancers are drawing an increasing number of inquiries from the medical community. We believe Cesium-131's ability to fight cancer and improve the quality of life for the men, women, and children who are battling these devastating cancers distinguishes it from other treatment options."
In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices including the GliaSite(R) radiation therapy system, the world's only liquid radiation balloon catheter device used in the treatment of brain cancer.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com.
Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Contact:
IsoRay Medical
(509) 375-1202
Info@Isoray.com
DG...
I know I have the right team with the Yankees! I'm hoping the APRI team will be half as successful..
As to Boston Red Sox, best moves they made were getting rid of Bobby Valentine and cleaning house. And APRI got rid of Damaj, maybe they have some more cleaning to do..
Anyway, I'm in APRI for the long haul. I get a little impatient, but that's the game. Fortunately, I have been selling some calls while waiting them out.
GLTA
Kingme...Not quite sure I understand the purpose of your link!
I recall having read that newsrelease in Jan 2012 where they said Abbott looks forward to launching Vitaros in Canada in 2012. Here we are 1 1/2 years later and no launch. So are you saying Abbott is deliberately delaying the launch so they don't have to pay the different milestones?
Please explain the link.
TIA
Why doesn't Abbott launch the already approved Vitaros?
Then they can keep working on their rendition of the product and when it is finally approved launch the "NEW" Improved version. Both versions could continue to sell and they could see which is more popular.
Why would they want to hold up launch of a product already approved and keep them from earning $$$$$?
Who are the major holders of SCRC?
I can only find one big whale, at almost 20 million shares, Urbanski.
Who are the others? Scheneiderman, Andrews, Pranskevicius???
TIA (just curious)
Alleyba1 ... Welcome to the board...
If you are a follower of Celtics you must take a look at NBRI. More Shock N Awe..
Chen Lin excerpt from The Life Sciences Report
TLSR: So you have another one you want to talk about?
CL: The last is a company called Apricus Biosciences Inc.(TBIO:OTCBB). The company makes an erectile dysfunction (ED) drug, like a Viagra (sildenafil citrate; Pfizer Inc. [PFE:NYSE]). Viagra is orally administered and can only help 50–55% of the population because people cannot take Viagra if they have a heart condition or diabetes, etc. Apricus' drug, Vitaros, can cover the rest because it is a cream that is applied locally. Major pharmaceutical companies like Abbott Laboratories (ABT:NYSE) and Novartis AG (NVS:NYSE) have already licensed this product, signing for milestone payments of almost $100M plus additional double-digit royalties, in most cases.
"I believe biotech is in the first leg of what could be a multiyear bull market."
But the company's market cap is still tiny. It's still around $85M. One day, one of the big pharmas will say, "Why do I need to pay hundreds of millions in royalties when I can buy the company for the same price?"
I like the company's new management, because it just got rid of the poison pill (shareholders' rights agreement) that opened it to a bidding war. Recent stock weakness was due to the company doing a secondary offering. I believe once the shares go to stronger hands, the stock can make a major move. It just got European Union (EU) approval for Vitaros. It will find new partners and get new milestone payments. For the next 6–12 months, we could have a dozens of positive catalysts. I believe the stock will move much higher. This is the only biotech stock that didn't go parabolic for me this year, but I think it could be the next to move.
TLSR: Where is it trading now?
CL: Around $2.50. With an $85M market cap and an ED drug that has billion-dollar per year potential, Apricus can be worth billions. And the company has already received EU approval. So Vitaros can be on the market in 6–12 months.
OT--Celtics. ...Mets vs Yankees??
We are in the 1st inning of an 18 inning game and its the mets vs the yankees they both cant hit
Granted, the Yankees aren't what they used to be, but comparing them to the mets! Can't you find a better analysis?
How about the Celtics and the Heat? LOL
I'm with you...
I payed .45 and picked up some more today. Couldn't decide between NBRI and SCRC, so I bought both!!!
GLTA
'onewhoknows2much'......
GREAT explanations.. I sincerely thank you for taking the time to elaborate on all those points. I understand where you are coming from and certainly agree, BIG TIME with you. I did not know that Erick Spangenberg is "Tecdev" ... No way is he selling in the forseable future.
Regarding the shorting, I will re read the filing tomorrow and try to find that part. I could very well be mistaken, again!
Thanks for your input and GLTA.
NBM
onewhoknows2much......
While I agree with you that just because you file to sell doesn't mean you will sell immediately, I have to disagree with you relative to when they will sell. I believe, after reading today's filing that at least one of the listed sellers is going to be selling into the market as they see fit. And I wouldn't doubt that the others are too, because they have a ton of free options coming. I hope not, as I own shares, but business is business and sometimes these financing people want their quick profits. I also read that they are allowed to sell short these shares. From the filing:
On April 22, 2013, Cyberfone Acquisition Corp. (“Acquisition Corp.”), a Texas corporation and newly formed wholly owned subsidiary of the Company entered into a merger agreement (the “Agreement”) with Cyberfone Systems LLC, a Texas limited liability company (“Cyberfone Systems”), TechDev Holdings LLC (“TechDev”) and The Spangenberg Family Foundation for the Benefit of Children’s Healthcare and Education (“Spangenberg Foundation”). TechDev and Spangenberg Foundation owned 100% of the membership interests of Cyberfone Systems (collectively, the ‘Cyberfone Sellers”).
Cyberfone Systems owns a foundational patent portfolio that includes claims that provide specific transactional data processing, telecommunications, network and database inventions, including financial transactions. The portfolio, which has a large and established licensing base, consists of ten United States patents and 27 foreign patents and one patent pending. The patent rights that cover digital communications and data transaction processing are foundational to certain applications in the wireless, telecommunications, financial and other industries. IPNavigation Group LLC (“IP Nav”), a Company founded by Erich Spangenberg and associated with the Cyberfone Sellers will continue to support and manage the portfolio of patents and retain a contingent participation interest in all recoveries. IP Nav provides patent monetization and support services under an existing agreement with Cyberfone Systems.
Pursuant to the terms of the Merger Agreement, Cyberfone Systems merged with and into Acquisition Corp with Cyberfone Systems surviving the merger as the wholly owned subsidiary of the Company (the “Merger”). The Company (i) issued 6,000,000 shares of common stock to the Cyberfone Sellers (the “Merger Shares”), (ii) paid the Cyberfone Sellers $500,000 cash and (iii) issued a $500,000 promissory note to TechDev (the “Note”). The Note is non-interest bearing and becomes due June 22, 2013, subject to acceleration in the event of default. The Company may prepay the Note at any time without premium or penalty. The transaction resulted in a business combination and caused Cyberfone Systems to become a wholly-owned subsidiary of the Company.
TecDevHoldings which received 6 million shares of MARA from the sale of Cyberfone is one of those listed. They also received $500,000 and a promisory note that is (actually was) due June 22, 2013.
This registration statement says that none of the proceeds go to the company and lists those shareholders who will benefit. The number of shares listed in the prospectus equals the number of shares being offered by those people. None in this are coming from the company.
So, are there gonna be more?
S-1 Filed, Shares being offered by selling shareholders
9,361,077 SHARES
MARATHON PATENT GROUP, INC.
Common Stock
This prospectus relates to the sale by the selling stockholders identified in this prospectus of up to 9,361,077 shares of our common stock, par value $0.0001, which includes 1,120,359 shares of common stock issuable upon the exercise of outstanding warrants.
There are no underwriting arrangements to sell the shares of common stock that are being offered by the selling stockholders hereunder. The prices at which the selling stockholders may sell shares will be determined by the prevailing market price for the shares or in privately negotiated transactions. We will not receive any proceeds from the sale of these shares by the selling stockholders. All expenses of registration incurred in connection with this offering are being borne by us, but all selling and other expenses incurred by the selling stockholders will be borne by the selling stockholders.
Our common stock is quoted on the OTC Bulletin Board under the symbol “MARA”. On June 24, 2013, the last reported sale price of our common stock as reported on the OTC Bulletin Board was $0.36 per share.
The table below sets forth certain information regarding the selling stockholders and the shares of our common stock offered by them in this prospectus. The selling stockholders have not had a material relationship with us within the past three years other than as described in the footnotes to the table below or as a result of acquisition of our shares or other securities. To the best of our knowledge, none of the selling stockholders is a broker dealer or an affiliate of a broker dealer other than as described in the footnotes to the table below.
38
Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission. The selling stockholders’ percentage of ownership of our outstanding shares in the table below is based upon 65,858,810 shares of common stock outstanding as of June 24, 2013.
Name and Address of
Stockholder Total Number
of Shares of
Common Stock
Held Prior to
Offering (1) Number of
Shares of
Common Stock
Offered
Pursuant to
this
Prospectus
Shares
Beneficially
Owned After
the Offering
(Number) (1) (3) Shares
Beneficially
Owned After
the Offering
(Percentage)
(1)(2)
John Stetson (4)
2,392,327 (5)
124,827(6)
2,267,500 3.44%
Daniel J. Allen
180,000(7)
180,000(7)
0 0
TATs of WA, Inc. DBP, Don Stangle, TTE (8)
187,500(9)
187,500(9)
0
0
Stuart Smith
1,312,500 (10)
375,000(11)
1,062,500 0.97%
Michael G. Stag LLC (12)
375,000(13)
375,000(13)
0 0
Sichenzia Ross Friedman Ference LLP (14)
387,500(15)
337,500(16)
50,000 0.10%
Abraham Belsky
187,500(17)
187,500(17)
0 0
Morris Fuchs
375,000(18)
375,000(18)
0 0
2004 Leon Scharf Irrevocable Trust FBO Rachel Beer and Descendants (19)
562,500(20)
562,500(20)
0 0
Joseph Hoch
562,500(21)
562,500(21)
0 0
Sandor Capital Master Fund (22)
1,668,750(23)
93,750(24)
1,575,000 3.05%
TechDev Holdings LLC (25) 6,000,000 6,000,000 0 0
TOTAL 9,361,077
Special Meeting starts at 11 AM
Document Security Systems, Inc.
First Federal Plaza
28 Main Street, Suite 1525
Rochester, New York 14614
Telephone: (585) 325-3610
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 20, 2013
To the Stockholders of Document Security Systems, Inc.:
The special meeting of stockholders of Document Security Systems, Inc., a New York corporation, will be held on June 20, 2013, at 11:00 a.m., local time, at Locust Hill Country Club, 2000 Jefferson Road, Pittsford, New York 14534, for the following purposes:
1. To approve a merger, including, but not limited to, the issuance of shares of DSS common stock and preferred stock (or, if Proposal 2 below is not approved by the DSS stockholders, $.02 warrants) and warrants (and the shares of common stock issuable upon conversion of the preferred stock or exercise of the $.02 warrants, as applicable, and exercise of the warrants) to the Lexington stockholders in connection with the merger contemplated by the Agreement and Plan of Merger, dated as of October 1, 2012, by and among DSS, Lexington and DSSIP, Inc., a wholly-owned subsidiary of DSS;
2. To amend DSS’s amended and restated certificate of incorporation to authorize a class of preferred stock and establish the associated rights and preferences thereof;
3. To amend DSS’s amended and restated certificate of incorporation to implement a staggered board of directors;
4. To amend DSS’s amended and restated certificate of incorporation to effect a reverse stock split of DSS’s issued and outstanding common stock within the range of one-for-two to one-for-four (with the exact amount, if any, to be determined prior to the completion of the merger based on the requirement of the NYSE MKT);
5. To approve the Document Security Systems, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan, as approved by the DSS board of directors on November 20, 2012;
6. To approve the adjournment of the DSS special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of any of the proposals referred to in (1) through (5) above; and
7. To conduct any other business as may properly come before the DSS special meeting or any adjournment or postponement thereof.
The DSS board of directors has determined that the merger, upon the terms and conditions set forth in the merger agreement, and the other transactions contemplated by the merger agreement are advisable and fair to, and in the best interests of, DSS and its stockholders. The board of directors makes its recommendation to the DSS stockholders after consideration of the factors described in this proxy statement/prospectus. The DSS board of directors unanimously recommends that DSS stockholders vote FOR each of the foregoing proposals.
The 10,000 share trade....
I don't fully understand, but I had an order in to sell 1,000 shares at $2.99. When I came home after the market closed I noted that my streamer showed a high of $3.025. When I checked to see if my trade went thru, it had not. I called Ameritrade and was told it was an exchange between two market makers to ensure liquidity for one of them. I asked why my $2.99 which was
3 1/2 cents cheaper wasn't executed, and was then given that explanation. He said that, that sometimes happens that they exchange shares to help each other out. I volunteered you mean manipulation to which he said no, it happens that way and is perfectly legal.
I don't understand why it had to go off so high when I think the bid/ask at that time was around 2.80/2.85..If they need liquidity why pay 20 cents higher?
NEWS
Marathon Patent Group's Wholly Owned Subsidiary, Relay IP, Inc., Files Patent Infringement Lawsuit Against 10 Defendants
Download PDFALEXANDRIA, VA -- (Marketwired) -- 06/18/13 -- Marathon Patent Group, Inc. (OTCBB: MARA) ("Marathon"), an intellectual property services and patent licensing company, announced today that its subsidiary Relay IP Inc, ("Relay") has filed a patent infringement lawsuit in the United States District Court for the District of Delaware against 10 named defendants.
Defendants include CBOE Holdings, Inc., The Nasdaq OMX Group, Inc., ActiveTick LLC, BATS Trading Inc., Lek Securities Corporation, Direct Edge ECN LLC and others.
Relay is asserting infringement related to U.S. Patent number 5,331,637, entitled Multicast Routing Using Core Based Trees. The lawsuit alleges that the Defendants have infringed, and continue to infringe, the claims of the patent in suit by using the accused IP Multicast systems and methods covered by the claims of the Relay patent.
About Marathon Patent Group
Marathon Patent Group ("Marathon") is patent licensing company that serves a wide range of patent holders and technologies from Fortune 500 to independent inventors. Marathon provides its clients advice and services that enable them to realize financial and strategic return on their intellectual property rights. Marathon's IP Licensing Division acquires patent assets, partners with patent holders, and monetizes patent portfolios through actively managed patent licensing campaigns. Marathon is based in Alexandria, Virginia. www.marathonpg.com
Forward Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Marathon Patent Group
Investor Relations
678-570-6791
IP Communications
Brody Berman Associates
212-683-8125
Shock and Awe...
Thanks for the invite. Look forward to "lurking" and "adding". You guys do a great job of providing your research and I hope that I can be as beneficial. I'm riding the coat tails on a few of your suggestions and can't wait for all the success we all will be enjoying.
Happy Fathers Day and GLTA
NBM
Thanks to all
Thanks for all the "Welcomes to the board" Was up late last night reading all the news releases and visiting the web site. Got my order in.
Have been in AUY, NG, PGLC and CDE .. but I like the prospects of this company.
Couple of weeks ago, I was in Cripple Creek,Colorado and went down a 1000 ft shaft to do the tourist thing at the Mollie Kathleen abandoned Gold Mine. Really found it very enjoyable and enlightening.
Thanks for the recommendation.
Good luck to all.
Celtics...Followed you over
Thanks for the lead.. I will be in ASAP.. Waiting on those Patent Plays!
bid .18 ask .19 .. I went in at .185 and they gave me 2,000 at .181